Policy & Regulation
Citius Pharmaceuticals collaborates with University of Pittsburgh to assess I/ONTAK in combination with pembrolizumab to treat recurrent or metastatic solid tumours
23 September 2022 -

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a US-based late-stage biopharmaceutical company, announced on Thursday that it has collaborated with Dr Haider Mahdi at the University of Pittsburgh in an investigator-initiated trial to assess I/ONTAK (denileukin diftitox or E7777) in combination with pembrolizumab intended to treat recurrent or metastatic solid tumours.

The company is also partnering with an investigator-initiated study at the University of Minnesota (UMN). The Phase one dose-finding study to assess I/ONTAK prior to tisagenleucel (KYMRIAH) CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.

I/ONTAK is a recombinant fusion protein that integrates the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.